November 30, 2006
Resverlogix Lead Compound RVX-208 Increases ApoA-I by 150% in First 24 Hours
Resverlogix Lead Compound RVX-208 Increases ApoA-I by 150% in First 24 Hours
Resverlogix Corp. (’Resverlogix’) (TSX: RVX), is pleased to announce that its clinical candidate, RVX-208, can rapidly increase plasma levels of ApoA-I up to 150% relative to control animals in the first 24 hours. The significance of this study is that a fast and sustained increase of ApoA-I are believed to benefit patients suffering from acute cardiovascular complications, such as acute coronary
Toyota Fund’s Otsuka Tops Peers With Shares of Carmaker, Units
Nov. 30 (Bloomberg) — Haruo Otsuka has turned his Toyota Group Stock Fund into Japan’s top performer by owning shares in 20 companies: Toyota Motor Corp. and its 19 affiliates.
HIV+ Man Jailed For Donating Blood
(Crown Point, Indiana) An Indiana man is in jail awaiting trial on charges of donating blood even though he knew he was HIV-positive. Michael D. Ivy, 45, is charged with selling HIV contaminated blood. If convicted he could face up to eight years in prison.
Mad Cow Risk Low For Hemophilia Patients
Patients with hemophilia and other blood-clotting disorders face an uncertain though probably very low risk of contracting the human form of mad cow disease from medicines made using donated plasma, health officials said Monday. CBS News: Mad Cow